Clinical Trial Update: Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. [Phase 3]

View source ↗

Summary

Open-label Phase 3 study in individuals aged 12-80 with severe asthma to assess reduction of background asthma medication while maintaining asthma control and c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Tezepelumab (tezepelumab)

Snippet

Sponsor: AstraZeneca | Conditions: Severe Asthma | Phase 3 | Status: ACTIVE_NOT_RECRUITING